Stock Price Quote

GLAND PHARMA LTD.

NSE : GLANDBSE : 543245ISIN CODE : INE068V01023Industry : Pharmaceuticals & DrugsHouse : Private
BSE1856.05-16.6 (-0.89 %)
PREV CLOSE ( ) 1872.65
OPEN PRICE ( ) 1872.65
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2691
TODAY'S LOW / HIGH ( )1851.15 1914.00
52 WK LOW / HIGH ( )971.6 2195.75
NSE1855.80-17.95 (-0.96 %)
PREV CLOSE( ) 1873.75
OPEN PRICE ( ) 1892.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1855.80 (86)
VOLUME 263703
TODAY'S LOW / HIGH( ) 1850.00 1914.00
52 WK LOW / HIGH ( )971 2194
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 20-03 1978
Management Info
Yiu Kwan Stanley Lau - Chairman Srinivas Sadu - Managing Director
Registered Office

Address Survey No. 143-148, 150 & 151,Near Gandimaisamma 'x' Roads, D. P. Pally,Dundigal Gandimaisamma Mandal, Medchal- Malkajgiri District,
Hyderabad,
Telangana-500043

Phone 040 30510999

Email gland@glandpharma.com / investor@glandpharma.com

Website www.glandpharma.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

07Jun Appointment of Director
Inter-alia, approved:- 1. has taken on record the completion of tenu..
07Jun Appointment of Chairman
Inter-alia, approved:- 1. has taken on record the completion of tenu..
03Jun Gland Pharma informs about analyst meet
Pursuant to Regulation 30 read with Part A of the Securities and Exchang..
27May Gland Pharma submits analyst meet inti
Pursuant to Regulation 30 read with Part A of the Securities and Exchang..
24May USFDA completes inspection at Gland Ph
The United States Food and Drug Administration (USFDA) has completed an..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit3214.1110433.25
Gross Profit 4326.88 14054.97
Operating Profit 4797.8515754.47
Net Sales 11748.341674.28

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  6588.50 (3.56%)
M.Cap ( in Cr)8452.97
Divi's Lab (BSE)
peergroup  4593.00 (3.24%)
M.Cap ( in Cr)121929.72
Fredun Pharma (BSE)
peergroup  918.15 (15.49%)
M.Cap ( in Cr)433.52
Glaxosmithkline Phar (BSE)
peergroup  2699.10 (2.72%)
M.Cap ( in Cr)45724.38
Mercury Laboratories (BSE)
peergroup  935.80 (7.43%)
M.Cap ( in Cr)112.30

Shareholding Pattern

PROMOTERS 57.86%
MUTUAL FUNDS/UTI 23.01%
NON-INSTITUTION 13.32%
FI/BANKS/INSURANCE 1.21%
GOVERNMENT 0%
FII 0%

About Gland Pharma Ltd.

Gland Pharma Ltd. was incorporated in the year 1978. Its today's share price is 1856.05. Its current market capitalisation stands at Rs 30578.74 Cr. In the latest quarter, company has reported Gross Sales of Rs. 36165.28 Cr and Total Income of Rs.38569.92 Cr. The company's management includes Allen Zhang, Yao Fang, Qiyu Chen, Essaji Goolam Vahanvati, Satyanarayana Murthy Chavali, Udoj J Vetter, Naina Lal Kidwai, Srinivas Sadu, Yiu Kwan Stanley Lau, P Sampath Kumar.

It is listed on the BSE with a BSE Code of 543245 , NSE with an NSE Symbol of GLAND and ISIN of INE068V01023. It's Registered office is at Survey No. 143-148, 150 & 151,Near Gandimaisamma 'x' Roads, D. P. Pally,Dundigal Gandimaisamma Mandal, Medchal- Malkajgiri DistrictHyderabad-500043, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are SR Batliboi & Associates LLP, SR Batliboi & Associates, LLP, Y Raghuram & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.